Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: Risk factors, correlation with DNA load, and outcomes

Blood

Volumn 97, Issue 4, 2001, Pages 867-874

  Nichols, W G ^a   Corey, L ^a   Gooley, T ^a   Drew, W L ^a   Miner, R ^a   Huang, M L ^a   Davis, C ^a   Boeckh, M ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P65; CORTICOSTEROID; GANCICLOVIR; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CYTOMEGALOVIRUS INFECTION; DEVICE; DISEASE COURSE; DRUG SENSITIVITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0035865528     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.4.867     Document Type: Article

References (27)

1. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
2. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
3. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of CMV disease: Risk factors and outcome
4. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis
5. Increased incidence of late CMV disease in allogeneic marrow transplant recipients after ganciclovir prophylaxis is due to a lack of CMV-specific T cell responses
6. Quantitation of cytomegalovirus: Methodologic aspects and clinical applications
7. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
8. Rising levels of human cytomegalovirus (HCMV) antigenemia during initial antiviral treatment of solid-organ transplant recipients with primary HCMV infection
9. Effects of treatment regimens in patients allografted for acute and chronic myelogenous leukemia
10. Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide
11. Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies
12. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: A prospective, randomized trial
13. Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia
14. 1994 Consensus conference on acute gvhd grading
15. Evaluation of CMV Brite kit for detection of cytomegalovirus pp65 antigenemia in peripheral blood leukocytes by immunofluorescence
16. Definitions of cytomegalovirus infection and disease
17. Development of a high-through-put quantitative assay for detecting herpes simplex virus DNA in clinical samples
18. Antiviral susceptibility testing of cytomegalovirus: Criteria for detecting resistance to antivirals
19. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients
20. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection
21. The dynamics of human cytomegalovirus replication in vivo
22. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy
23. Current management of cytomegalovirus retinitis in AIDS: Update on ganciclovir and foscarnet for CMV infections
24. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients: Australasian Bone Marrow Transplant Study Group
25. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation
26. A comparison of prophylactic vs preemptive ganciclovir to prevent cytomegalovirus disease in T-depleted volunteer unrelated donor bone marrow transplantation